alexa Suppression of bladder cancer cell tumorigenicity in an athymic mouse model by adenoviral vector-mediated transfer of LRIG1.
Molecular Biology

Molecular Biology

Journal of Cytology & Histology

Author(s): Li F, Ye ZQ, Guo DS, Yang WM

Abstract Share this page

Abstract Previous in vitro studies demonstrated that leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), a negative regulator of EGFR, is a novel agent for suppressing bladder cancer. However, the role that LRIG1 plays in bladder cancer growth in vivo has not been elucidated in animal or clinical studies. Thus, to evaluate the suppressive effects of LRIG1 on human invasive bladder cancer in vivo, we transferred LRIG1 into athymic mice bearing T24 invasive bladder cancer xenografts mediated by an adenoviral vector. Correlations between LRIG1 expression and tumorigenicity, EGFR expression, xenograft proliferation and angiogenesis were assessed, respectively. The results indicated that tumor volume growth was retarded via Ad-LRIG1 intratumoral injection. In addition LRIG1 upregulation was well correlated with a reduction in EGFR expression and the proliferation rate of xenografts. Furthermore, microvessel densities were reduced and correlated with Ad-LRIG1 administration. No significant macroscopic and microscopic pathological abnormality was observed in the liver, kidney and lungs of Ad-LRIG1-administered mice. This new insight provides evidence that downregulation of EGFR expression by LRIG1 may comprise a potential novel and safe therapeutic approach for improving the prognosis of invasive bladder cancer. This article was published in Oncol Rep and referenced in Journal of Cytology & Histology

Relevant Expert PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]ne.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords